1294PPHASE I STUDY FOR CERITINIB (LDK378) IN JAPANESE PATIENTS WITH ALK GENETIC ALTERATIONS

Haruyasu Murakami,1 Takashi Seto,2 Toshiaki Takahashi,1 Atsushi Horiike,3 Fumihiko Hirai,2 Naoko Suenaga,4 Takeshi Tajima,4 Kota Tokushige,4 Anthony L Boral,5 Matthew Robson,4 and Makoto Nishio3 1Shizuoka Cancer Center, Shizuoka, Japan; 2National Kyushu Cancer Center, Fukuoka, Japan; 3The Cancer Institute Hospital of JFCR, Tokyo, Japan; 4Novartis Pharma K.K., Tokyo, Japan; 5Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA